Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared. This study retrospectively evaluated 373 patient...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Hepatol Commun
Главные авторы: Choi, Won‐Mook, Choi, Jonggi, Lee, Danbi, Shim, Ju Hyun, Lim, Young‐Suk, Lee, Han Chu, Chung, Young‐Hwa, Lee, Young‐Sang, Park, Sook Ryun, Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Lee, So Jung, Kim, Kang Mo
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2020
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327222/
https://ncbi.nlm.nih.gov/pubmed/32626838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1523
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы